📰 Stat Facts News
Page 2 - Stat Facts News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Stat Facts. Real-time updates on events, politics, business and more.
December 18, 2023
Press Release Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes ...
December 11, 2023
/PRNewswire/ -- Laekna (2105.HK), a clinical-stage biotechnology company, announced reporting the results of a phase Ib study to evaluate the efficacy and...
November 3, 2023
Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma after experimental treatment with CAN-2409 Estimated overall...
November 2, 2023
(BPT) - Thirty-nine years ago, Hector and Nora met right after high school, marrying just eight months later — and have been inseparable ever since. Over the decades, the two have grown …
November 1, 2023
(BPT) - Thirty-nine years ago, Hector and Nora met right after high school, marrying just eight months later — and have been inseparable ever since. Over the decades, the two have grown …
October 22, 2023
BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 22, 2023--
October 22, 2023
Media Release TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to...
October 20, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two...
September 5, 2023
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK® (tisotumab vedoti...
September 5, 2023
Company AnnouncementPhase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for presentation at a future medical meetingGenmab and Seagen to engage in discussions with regulatory authoritiesCOPENHAG...